<DOC>
	<DOC>NCT01367665</DOC>
	<brief_summary>This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.</brief_summary>
	<brief_title>STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriate Eastern Cooperative Oncology Group (ECOG) Performance Status 02 Concurrent antitumor therapy Completion of the most recent antitumor therapy less than 21 days prior to the initiation of treatment Uncontrolled medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>